Pithy intro text about the biopharma milieu. Novartis cites more tumor reports after Zolgensma Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, its gene therapy. Amgen announced new findings showing Repatha (evolocumab) reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density.